Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5290275
Max Phase: Preclinical
Molecular Formula: C17H14ClN3O
Molecular Weight: 311.77
Associated Items:
ID: ALA5290275
Max Phase: Preclinical
Molecular Formula: C17H14ClN3O
Molecular Weight: 311.77
Associated Items:
Canonical SMILES: O=C(Nc1nc2cc(Cl)ccc2[nH]1)C1CC1c1ccccc1
Standard InChI: InChI=1S/C17H14ClN3O/c18-11-6-7-14-15(8-11)20-17(19-14)21-16(22)13-9-12(13)10-4-2-1-3-5-10/h1-8,12-13H,9H2,(H2,19,20,21,22)
Standard InChI Key: YUYWNWMJKMVZLQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 311.77 | Molecular Weight (Monoisotopic): 311.0825 | AlogP: 3.96 | #Rotatable Bonds: 3 |
Polar Surface Area: 57.78 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.83 | CX Basic pKa: 2.34 | CX LogP: 3.99 | CX LogD: 3.97 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.77 | Np Likeness Score: -1.31 |
1. Meduri B, Pujar GV, Durai Ananda Kumar T, Akshatha HS, Sethu AK, Singh M, Kanagarla A, Mathew B.. (2021) Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development., 222 [PMID:34126459] [10.1016/j.ejmech.2021.113574] |
Source(1):